IN8bio, Inc. Common Stock (INAB) is a publicly traded Healthcare sector company. As of July 9, 2026, INAB trades at $1.36 with a market cap of $13.33M and a P/E ratio of -0.55. INAB moved +1.45% today. Year to date, INAB is -41.03%; over the trailing twelve months it is -37.27%. Its 52-week range spans $1.17 to $12.53. Analyst consensus is strong buy with an average price target of $5.00. Rallies surfaces INAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IN8bio’s DeltEx DRI Doubles Glioblastoma Progression-Free Survival to 16.1 Months: IN8bio published Phase 1 INB-200 trial results demonstrating repeat-dose DeltEx DRI doubled median progression-free survival to 16.1 months versus a 6.9-month standard-of-care benchmark in newly diagnosed glioblastoma, with no dose-limiting toxicities reported. Repeat-dose patients also achieved median overall survival of 19.5 months, exceeding the ~14.6-month historical standard-of-care median.
| Metric | Value |
|---|---|
| Price | $1.36 |
| Market Cap | $13.33M |
| P/E Ratio | -0.55 |
| EPS | $-2.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.53 |
| 52-Week Low | $1.17 |
| Volume | 33.55K |
| Avg Volume | 0 |
| Revenue (TTM) | $487.00K |
| Net Income | $-18.98M |
| Gross Margin | 0.00% |
3 analysts cover INAB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.00.